CommercialCoverageMedium impact
Tzield (teplizumab-mzwv)
Blue Cross & Blue Shield of Mississippi·MS · Endocrinology, Pediatrics, Internal Medicine +1 more·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBSMS has updated their policy for Tzield (teplizumab-mzwv) injections, now considering them not medically necessary due to uncertainties about treatment benefits. All Tzield injections and related administration services will be denied unless approved through prior authorization.
Action Required
Immediately: Stop billing HCPCS code J9381 (teplizumab-mzwv injection) for BCBSMS patients without prior authorization. Billing team must flag all Tzield treatment requests for prior auth review before service delivery. Update billing system to require PA for J9381. Claims submitted without PA approval will be denied as not medically necessary.